| Literature DB >> 35040667 |
Alexander Muik1, Bonny Gaby Lui1, Ann-Kathrin Wallisch1, Maren Bacher1, Julia Mühl1, Jonas Reinholz1, Orkun Ozhelvaci1, Nina Beckmann1, Ramón de la Caridad Güimil Garcia1, Asaf Poran2, Svetlana Shpyro1, Andrew Finlayson1, Hui Cai3, Qi Yang3, Kena A Swanson3, Özlem Türeci1,4, Uğur Şahin1,5.
Abstract
The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number of mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 reference strain), Beta (B.1.351), Delta (B.1.617.2), or Omicron pseudoviruses with sera of 51 participants who received two or three doses of the messenger RNA (mRNA)-based COVID-19 vaccine BNT162b2. After two doses, Omicron-neutralizing titers were reduced >22-fold compared with Wuhan-neutralizing titers. One month after the third vaccine dose, Omicron-neutralizing titers were increased 23-fold relative to their levels after two doses and were similar to levels of Wuhan-neutralizing titers after two doses. The requirement of a third vaccine dose to effectively neutralize Omicron was confirmed with sera from a subset of participants using live SARS-CoV-2. These data suggest that three doses of the mRNA vaccine BNT162b2 may protect against Omicron-mediated COVID-19.Entities:
Mesh：
Substances：
Year: 2022 PMID： 35040667 DOI： 10.1126/science.abn7591
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728